Figure 1From: Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy Progression free survival (PFS) according to maintenace Bevacizumb (mBev) combined or not to hormonal therapy (HT) in hormonal receptor positive patients. Back to article page